Table 1.
Risk group assignment by risk group definition
| Risk group assignment | Risk group stratification definition | |
|---|---|---|
|
D‐series (1997‐2004) |
ARST‐series (2004‐2013) |
|
| Low |
D9602 (NCT00002995): (ERMS only) Subset A: Fav site, any size, Stage 1, Group I and II, N0; Fav site, any size, Stage 1, Group III, N0, (orbit only); Unfav site, ≤ 5cm, Stage 2, Group I, N0, Nx; Therapy: VA x 45 wk Subset B: Fav site, any size, Stage 1, Group II, N1; Fav site, any size, Stage 1, Group III, N1 (orbit only); Fav site (except orbit), any size, Stage 1, Group III, N0, N1; Unfav site, ≤5 cm, Stage 2, Group II, N0, Nx; Unfav site, ≤5 cm with N1 or >5 cm any size, Stage 3, Group I/II, N0, Nx, N1 Therapy similar to D9803 |
ARST0331 (NCT00075582): (ERMS only) Subset 1: Stage 1, Group I and II, N0; Stage 1, Group III, N0, Nx, (orbit only); Stage 2, Group I, N0, Nx, and Group II; Therapy: VAc x 4, VA x4 Subset 2: Stage 1, Group III, N0, Nx, (non‐orbital); Stage 3, Group I/II Therapy VAc x 4, VA x 12 |
| Intermediate |
D9803 (NCT00003958) Stage 1‐3, Group I‐III, ARMS; Stage 2/3, Group III, ERMS; Stage 4, Group IV, ERMS, <10 years Therapy: VAC vs VAC/VTC |
ARST0531 (NCT00354835) Stage 2/3, Group III, ERMS; Stage 1‐3, Group I‐III, ARMS Therapy: VAc vs VAc/VI |
| High |
D9802 (NCT00003955) Stage 4, Group IV, except ERMS <10 y Therapy: I ± V; VAC |
ARST0431 (NCT00354744) Stage 4, Group IV Therapy: VDc/IE/I/VAc |
Abbreviations: ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; Fav, favorable; I, irinotecan; N0, No regional nodal involvement; N1, regional nodal involvement; Nx, nodal involvement unknown; Unfav, unfavorable; V, vincristine; VA, vincristine/actinomycin; VAc, vincristine, actinomycin/cyclophosphamide (dose 1.2 gm/m2); VAC, vincristine, actinomycin/cyclophosphamide (dose 2.2 gm/m2); VDc, vincristine/doxorubicin/cyclophosphamide; IE, Ifosfamide/etoposide; VTC, vincristine, topotecan, cyclophosphamide.